Yantai Justaware

Yantai Justaware Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary Just-Body platform to engineer next-generation biologics, including bispecific antibodies and antibody-drug conjugates (ADCs). Its lead programs target high-value oncology markers such as Claudin-18.2 and PD-1/CTLA-4, aiming to address unmet medical needs in gastrointestinal and lung cancers. Justaware operates integrated R&D facilities that span from early-stage drug discovery to clinical development.